Market Intelligence for Microtubule Dynamics Modulation and High-Purity Enzymatic Assay Reagents
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TTL (Tubulin Tyrosine Ligase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | TTL Recombinant Protein (Full-Length); Human TTL (1-377 aa), Sequence Verified by Mass Spec, Purity >95% (SDS-PAGE/HPLC), Endotoxin <1 EU/µg, HEK293 Expressed, Theoretical MW 43 kDa | View TTL Products |
| Antigen (Mutant) | TTL E302A Catalytic Dead Mutant (Mechanism-of-action control, ATP-binding defective) & Custom Point-Mutation Service | View TTL Products |
| Substrate (TUBA1A) | Recombinant human α-tubulin (TUBA1A), C-terminal tyrosine removed form available, for enzymatic assays; natural substrate for TTL | View TUBA1A Products |
| Gene Delivery | TTL Lentivirus Premade Particles; Full-length ORF (NM_003286), Puromycin selection, Titer >10⁸ TU/mL, Endotoxin controlled, for stable cell line generation | View TTL Products |
| Benchmark Ab (Anti-TTL) | Anti-TTL Rabbit Monoclonal Antibody; High-specificity clone for Western blot, IF, and IHC. Sequence Verified. | View TTL Products |
| Functional Validator | Anti-Detyrosinated Tubulin (Glu-Tubulin) Antibody; Rabbit mAb clone GT-1, Validated for WB/IHC (Cell-based detyrosination readout) | View TTL Products |
| Validator (siRNA) | TTL siRNA Set (three target-specific sequences, >70% knockdown efficiency guarantee, includes scrambled control; for knockdown verification and loss-of-function models) | View TTL Products |
| Related Target A: VASH1 | VASH1 Recombinant Protein; Tubulin detyrosinase (carboxypeptidase); functional antagonist of TTL in the tubulin tyrosination cycle | View VASH1 Products |
| Related Target B: TTLL4 | TTLL4 (Tubulin Tyrosine Ligase Like 4); Selectivity counter-screening: closest homolog for off-target liability assessment | View TTLL4 Products |
Critical Assay Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Inhibitor Screening | High-purity TTL (Theoretical MW 43,062 Da), LC-MS verified intact mass, <5% aggregated species (SEC validated), >95% purity, Endotoxin <1 EU/µg. Suitable for DSF, SPR, and biochemical tyrosination assays. |
| Catalytic Mechanism & Specificity Control | Catalytically dead E302A mutant available for negative control; custom point-mutation service; sequence verified. |
| Substrate Specificity & Counter-screen | Recombinant TUBA1A with authentic C-terminal sequence (ΔTyr form available) for substrate-binding assays; also offer recombinant α-Tubulin for orthogonal specificity. |
| Intracellular Target Engagement & Cell Model | Matched Lentivirus + Anti-Glu-tubulin antibody combo for detyrosination readout; Premade Lentivirus for stable cell line generation to mimic TTL-deficient phenotypes. |
| Family Selectivity (vs TTLLs) | TTLL4 and TTLL6 recombinant proteins strictly verified by mass spec for counter-screening panels. |
| False Positives & Off-Target Liability | Endotoxin controlled (<1 EU/µg) proteins and validated siRNA for specific phenotypic readouts; include scrambled siRNA control. |
Live TTL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting the "Tubulin Code" is intensifying, with major players shifting focus from traditional non-specific antimitotics to modulators of tubulin post-translational modifications. TTL (Tubulin Tyrosine Ligase) is a critical regulator of the tubulin tyrosination cycle; its down-regulation is heavily correlated with aggressive solid tumors, metastasis, and resistance to taxane-based chemotherapies. As first-generation therapies targeting microtubule dynamics reach clinical limitations, the next wave of R&D is targeting specific modulation of the tubulin tyrosination cycle, including allosteric inhibition and PROTAC-mediated degradation to overcome challenges with ATP-competitive binding sites. Combinations with microtubule-targeting agents (MTAs) like taxanes and vinca alkaloids are being explored to overcome resistance. Additionally, TTL's role in neuronal axon maintenance opens possibilities for neurodegenerative disease indications such as Alzheimer's disease and ALS. While no small-molecule TTL inhibitor has yet reached the clinic, preclinical validation is intensifying across solid tumor models and neuronal contexts.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Academic consortia, Emerging Biotech | Solid Tumors (Lung, Breast, Colorectal) | Enzymatic turnover & binding assay (Need high-purity TTL + ATP monitoring; TTL-TUBA1A complex reconstitution) |
| Allosteric Inhibitor | Institut Curie, Stanford Labs | Neuroblastoma, Solid Tumors | Tubulin binding displacement assay (Need TTL-TUBA1A complex reconstitution; mutant protein panels) |
| PROTAC Degrader | Targeted protein degradation Biotechs, Early-Stage Innovators | Refractory Cancers, Metastatic Breast Cancer | Cell-based degradation & detyrosination readout (Need Lentivirus + Glu-tubulin antibody; stable cell lines) |
| CNS-Penetrant Inhibitor | Neurodegeneration-focused Pharma | Alzheimer's Disease, ALS | Mutant protein panel (Need disease-associated TTL variants; brain penetration assay) |
| Biomarker Diagnostic | Translational Research Hubs | Chemo-resistance profiling | Target validation (Need siRNA sets for clinical correlation modeling; Benchmark antibodies) |